Clinical Trial Search

Primary: Total Number of AKs in Treatment Area — 3.0; 2.1; 4.7 lesions — p=0.0166

Primary: Sputum Culture Conversion (2 Negative Cultures) Using Liquid Media — 48; 63; 66; 55 days

Primary: Percentage of Participants With Both a Change From Baseline in Hyperhidrosis Disease Severity Scale (HDSS) Score by ≥ 2 Points and a Change From Baseline in Gravimetric…

Primary: Change in Melasma Area and Severity Index (MASI) Score — -11.4 units on a scale — p=0.006

Primary: Maximal Percentage Change From Pre-exercise Baseline Forced Expiratory Volume in 1 Second (FEV1) to the Minimum FEV1 Collected Within 60 Minutes Following the Exercise…

Primary: Change in Hearing Loss After 4 Weeks of Treatment — -1.114; -1.914 decibels (dB)

Primary: 2 Hour C-peptide AUC in Response to MMTT — 358; 495 pmol/L — p=0.81

Primary: Change in Fasting Insulin Level — -2.47; -0.08; -1.16; 2.79 mU/L — p=<0.0001

Primary: Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA — 39.05 ng/mL

Primary: Change From Baseline to Week 24 for Plasma Pyridoxal-5' Phosphate (PLP) — -254.96; -564.27; 3.13; -397.72 ng/mL — p=0.0285

Primary: Steady-state C12 hr on Days 14, 18, and 21 After Weight-based Dosing — 7.870; 10.517 ng/mL

Primary: Participants Who Reported Reductions in Alcohol Consumption — 3 Participants

Primary: Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation — 13; 6; 8; 21 Participants

Primary: Percentage of Participants With Grade III-IV Acute GVHD by Day 100. — 10 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 87.9; 93.3; 100.0; 96.6 percentage of participants